---
layout: post
title: "COVID-19: Developing Drugs and Biological Products for Treatment or Prevention; Guidance for Industry; Availability"
date: 2026-02-05 18:57:41 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-25952
original_published: 2023-11-24 00:00:00 +0000
significance: 8.00
---

# COVID-19: Developing Drugs and Biological Products for Treatment or Prevention; Guidance for Industry; Availability

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** November 24, 2023 00:00 UTC
**Document Number:** 2023-25952

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "COVID-19: Developing Drugs and Biological Products for Treatment or Prevention." The purpose of this guidance is to assist sponsors in the clinical development of drugs and biological products for the treatment or prevention of COVID-19. This guidance describes FDA's current recommendations for phase 2 and phase 3 trials with a focus on trial population, trial design, efficacy endpoints, safety considerations, and statistical considerations. This guidance supersedes the guidance of the same name initially issued on May 19, 2020, and reissued on February 22, 2021.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/11/24/2023-25952/covid-19-developing-drugs-and-biological-products-for-treatment-or-prevention-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2023-25952

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
